Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.9165
- Book/Share -0.0779
- PB -2242.0157
- Debt/Equity -385.1421
- CurrentRatio 0.7358
- ROIC 0.1416
- MktCap 409028897900.0
- FreeCF/Share 10.2929
- PFCF 22.4261
- PE 108.8588
- Debt/Assets 0.5138
- DivYield 0.0279
- ROE 1.4231
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
| Upgrade | ABBV | Daiwa Securities | Neutral | Outperform | -- | $214 | Aug. 7, 2025 |
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
Drugmaker AbbVie says tax reform, not tariffs, would drive U.S. manufacturing
Published: April 25, 2025 by: Market Watch
Sentiment: Neutral
AbbVie Inc. took a little shot at the Trump administration's trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing.
Read More
AbbVie Beats on Q1 Earnings & Sales, Raises '25 EPS View
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of immunology drugs Rinvoq and Skyrizi.
Read More
AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
AbbVie Inc.'s Q1 earnings show an 8.4% revenue increase, driven by strong performance in immunology, neuroscience, and oncology divisions, with Skyrizi and Rinvoq leading growth. Despite Humira's patent expiry, AbbVie successfully transitioned to new revenue sources, has upgraded its full-year EPS estimates, and maintains a robust dividend yield of over 3.6%. ABBV is expanding into the obesity drug market with a promising amylin analog, potentially doubling its share price value if successful, although it is very early days.
Read More
AbbVie Stock Rises on Stronger-Than-Expected Results, Profit Outlook Lift
Published: April 25, 2025 by: Investopedia
Sentiment: Positive
AbbVie (ABBV) on Friday reported first-quarter results that came in above analysts' estimates, and lifted its full-year profit guidance.
Read More
ABBV Earnings Beat, Exposure to Tariffs, ABBV & UNH Options Trades
Published: April 25, 2025 by: Schwab Network
Sentiment: Positive
David Kaplan says AbbVie (ABBV) shows "unusually strong growth compared to peers." While he notes parts of its business is exposed to tariffs, the pharmaceutical and medical device industries are typically resilient to macro headwinds, and he believes AbbVie can withstand most.
Read More
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.31 per share a year ago.
Read More
AbbVie lifts guidance as Q1 results top expectations
Published: April 25, 2025 by: Proactive Investors
Sentiment: Positive
Abbvie Inc (NYSE:ABBV) shares moved higher after it reported strong results for the first quarter of 2025 and raised its full-year profit guidance. The company now expects adjusted earnings per share (EPS) in the range of $12.09 to $12.29, up from its earlier guidance of $11.99 to $12.19.
Read More
If You Wanted To Buy AbbVie and Didn't, There's Still Time To Buy
Published: April 25, 2025 by: MarketBeat
Sentiment: Positive
If you have been or are thinking about getting into AbbVie NYSE: ABBV, there is still time to do so. The AbbVie stock price is in a sustained uptrend and will set new all-time highs repeatedly over time.
Read More
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
Buy, Sell or Hold ABBV Stock? Key Tips Ahead of Q1 Earnings
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q1 results later this week.
Read More
Final Trades: 3M, Abbvie, Salesforce and Intuitive Surgical
Published: April 22, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors – Contact Levi & Korsinsky
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
After Tariff Flush, a Fresh Look at AbbVie Pharma (ABBV)
Published: April 15, 2025 by: See It Market
Sentiment: Positive
In my 2025 Outlook, I picked AbbVie Pharmaceuticals (NYSE: ABBV) as one to watch this year. Here is what I wrote: AbbVie (ABBV) AbbVie primarily works in immunology, oncology, neuroscience, eye care, and virology.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
Read More
Final Trades: TJX, Meta, Abbvie and Taiwan Semi
Published: April 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
Published: April 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=142536&wire=1 or contact Joseph E. Levi, Esq.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Robert A. Michael CPA
- Employees 55000